The expression of several cancer stem cell (CSC)-related markers has been confirmed in non-small cell lung cancer (NSCLC). The aim of this study was to clarify the clinical role of CSC-related markers in patients with NSCLC undergoing induction chemoradiotherapy (CRT). Fifty patients with clinically diagnosed N2 or N3 NSCLC who underwent induction CRT with docetaxel and cisplatin concurrently with thoracic radiation followed by surgery were examined in this study. The expressions of CSC related markers (CD133, ALDH1, ABCG2, and Bmi-1) were examined using immunohistochemical staining in surgically resected specimens. Among the 50 patients, 20 patients had no residual tumor cells in the resected specimen when examined pathologically; CSC-related marker expressions and their correlation to survival were evaluated in the other 30 patients. After a median follow-up period of 72 months, the 5-year overall survival rate of the patients with CD133-positive or ALDH1-positive specimens was significantly worse than that of the patients with both CD133-negative and ALDH1-negative expressions (44.9% vs. 90.0%, respectively; P = 0.042). In a multivariate analysis, CD133 and ALDH1 negativity (P = 0.047) and cN2-3 single station metastasis (P = 0.03) were significant independent prognostic factors for prolonged survival. The expressions of CSC-related markers after CRT were 3 significantly correlated with a poor prognosis in patients with NSCLC. The development of therapeutic strategies including adjuvant therapy that take CSC-related marker positivity into consideration is likely to be a key factor in further improvements of the prognosis of patients undergoing trimodality therapy. 
Prognostic impact of cancer stem cell-related markers in non-

INTRODUCTION
Lung cancer is the leading cause of death among patients with malignant tumors worldwide. For locally advanced non-small cell lung cancer (NSCLC), multimodal therapy including chemotherapy, radiotherapy and surgery can improve the survival of patients, compared with single-treatment modalities. Definitive chemoradiotherapy is one of the treatments of choice for locally advanced NSCLC, especially when N2 or N3 disease is apparent. While surgical resection after induction therapy is not currently considered an established standard approach, surgery after induction therapy is often performed by experienced institutions worldwide [1] . Stupp et al. recently reported an excellent outcome (5-year survival rate of 40%) for stage IIIB patients who were treated with docetaxel and cisplatin followed by accelerated radiotherapy and surgery [2] . We also reported a promising clinical outcome of trimodality therapy for NSCLC patients with stage III disease [3] .
To further improve the outcome of induction therapy, prognostic factors for induction therapy needed to be identified. The histological response in resected specimens is usually examined, since a pathological complete response (pCR) or mediastinal downstaging are prognostic factors of induction therapy followed by surgical treatment. However, the rate of pCR or downstaging is approximately 30%, and the exploration of novel prognostic factors may be useful [1] [2] [3] .
Recently, cancer stem cells (CSCs), which are characterized by the capacity for self-renewal and pluripotency, have been attracting interest as a source of cancer cells [4] . Va rious molecules are being investigated as putative markers of CSCs in malignancies including lung cancer [5] . CD133, which was initially described as a surface antigen specific for human hematopoietic stem cells [6, 7] , is now being used to identify and isolate putative CSC populations from malignant tumors including cancers of the brain, prostate, liver, pancreas, and colon as well as melanomas [8] [9] [10] [11] [12] [13] [14] . CD133
has also been used to isolate cancer-initiating (stem) cells from lung cancer [15] ;
however, its clinical role in lung cancer remains unclear. As another candidate marker for CSCs, aldehyde dehydrogenase (ALDH), which is known to occur in brain tumors and breast cancer, is widely regarded as a surface marker of CSCs in lung cancer [16] [17] [18] . Serrano et al. reported that ALDH-positive lung cancer stem-like cells have longer telomeres but similar telomerase activity levels, compared with the non-CSC fraction [19] .
A previous study reported that the expression of some CSC-related markers was related to a poor prognosis among patients with initially resected NSCLC, suggesting their potential use as prognostic markers such as CD133, ATP-binding cassette 6 superfamily G member 2 (ABCG2), Bmi-1, and Octamer-4 [20] [21] [22] . Indeed, CSCs are known to have drug or radiation-resistant features [23, 24] . These reports suggest that the presence of residual CSC-like cells in specimens treated with induction CRT may indicate the resistance of the cancer cells and may be related to a poor prognosis.
In this study, we examined the expression of four CSC-related markers (CD133, ALDH1, ABCG2, and Bmi-1) using immunohistochemical (IHC) staining in surgically resected specimens that had been subjected to induction CRT and evaluated the prognostic impact of these CSC-related markers in viable cells after induction therapy.
MATERIALS AND METHODS
Patients, treatment plan and study design
A total of 50 patients with locally advanced N2 or N3 NSCLC who underwent induction chemotherapy concurrently with thoracic radiation followed by surgery 
IHC staining
Surgical specimens of the primary lesion were evaluated using IHC staining in the cases with residual tumor cells. Evaluations of pre-treatment biopsy samples of the primary lesion could not be performed because sufficient amounts of the samples necessary for the evaluation of CSC-related markers using IHC staining could not be obtained in many cases. and Bmi-1 negative <5%, positive >5% [27] . Omission of primary antibody served as a negative control in each marker. The bronchial epithelial cells (in ALDH1, ABCG2, and Bmi-1) or macrophages (in ALDH1) were used as internal control (Supplementary fig.   1 ). In CD133, strongly stained sample was used as positive control.
Statistical analysis
In this study, the overall survival (OS) period was defined as the primary endpoint and the disease-free survival (DFS) period was defined as the secondary endpoint. The OS and DFS were calculated from the date of initial treatment until the date of death or the last follow-up for OS and until confirmed disease recurrence or death for DFS.
The baseline characteristics of the patients were compared using the Wilcoxon rank sum test for continuous variables and the Fisher exact test for categorical variables, as appropriate. A univariate analysis of OS and DFS was performed using the Kaplan-Meier method with logrank testing, and a multivariate analysis was performed using the Cox proportional hazard model. All the data were analyzed using JMP, version 9.0.0 (SAS Institute Inc, Cary, NC). For each analysis, probability values of less than 0.05 were considered significant.
RESULTS
Expression of CSC related markers in NSCLC
Among the 50 surgically resected specimens, viable tumor cells remained in the specimens from 30 patients. Among these 30 patients, 9 patients (30%) were positive for CD133 expression, 18 patients (60%) were positive for ALDH1 expression, 14 patients (47%) were positive for ABCG2 expression, and 25 patients (83%) were positive for Bmi-1 expression. Details of each marker expression in each patient are shown in Supplementary table 1. Examples of the IHC staining patterns are shown in Fig. 1, Supplementary fig. 1 
Clinical outcomes and impact of CSC-related marker expressions
The relationships between the CSC-related marker statuses and the clinical outcomes were examined. After a median follow-up duration of 72 months, nine patients had died. Seventeen patients had experienced a disease relapse. The 3-year and (Fig. 2) . The relationships between other clinicopathological factors and survival were also examined.
The selected clinicopathological factors were as follows: age, sex, smoking history, (Table 3) .
Postoperative adjuvant chemotherapy was performed in 15 of the 30 patients.
Although the number was small, the CSC related marker status of the 15 patients who received adjuvant chemotherapy was not significantly related to the OS or DFS periods.
DISCUSSION
We showed that the positive expression of CD133 or ALDH1 is independent predictor of disease relapse and a poor prognosis among patients who have received induction CRT using docetaxel and cisplatin. The positive expression of CD133 or ALDH1 in resected specimens may be an indicator of tumor resistance, indicating the failure to control preexisting micrometastasis or to prevent metastasis during or after CRT.
The four markers that were examined in this study have been previously reported as candidate CSC-related proteins in NSCLC. Tirino et al. reported that CD133-positive cells isolated from surgically resected specimens of previously untreated NSCLC were able to give rise to spheres and to act as tumor-initiating cells [28] . It has been also reported that CD133 positive endothelial progenitor cells are found in previously untreated frozen NSCLC tissue obtained by surgery and seem to be related to vasculogenesis [29] . On the other hand, Salnikov et al. reported that CD133 was indicative of a resistance phenotype but was not a prognostic marker for survival in surgically resected specimens of previously untreated NSCLC [30] . The authors showed a significant association between the expression of resistance-related proteins, such as glutathione S-transferase, thymidylate synthase, catalase, O 6 -methylguanine-DNA CD133-positive fraction after both acute cytotoxicity and in cells with a stable cisplatin-resistant phenotype [23] . These findings are consistent with our result, in which the expression of CD133 in surgically resected specimens after induction CRT was related to an unfavorable outcome. ABCG2, a member of the ATP binding cassette (ABC) transporter superfamily, is an important determinant of the side population (SP)
phenotype [31] . SP cells with stem cell-like capabilities marked by ABCG2 have been found in a variety of hematologic and solid malignancies, as well as NSCLC [32, 33] .
Bmi-1 is a member of the Polycomb group family of proteins, which act as epigenetic chromatin modifiers [34, 35] . Bmi-1 is known to be a key regulator in the self-renewal of stem cells [36] , and a recent report has shown that the expression of Bmi-1 in surgically resected specimens was a significant prognostic factor of a poor outcome in lung adenocarcinoma [20] . In our study, no obvious relation was seen between the expression of ABCG2 or Bmi-1 and patient outcome. This discrepancy may be due to differences in the kinds of samples that were examined, since our specimens had been treated with CRT. In addition to the markers examined in the present study, other CSC-related markers have also been reported. Further study examining the impact of such markers on trimodality therapy is necessary.
Surgically resected specimens that had been treated with CRT were used in this is a concern. Indeed, the expression of CD133 was observed in a very limited portion of the surgically resected specimens in the present study.
What is the appropriate therapeutic strategy for tumors with positive CSC-related makers? In our knowledge, there is no relevant therapeutic strategy to specifically target cells with CSC-like phenotype in lung cancer. Of interest, histone deacetylase inhibitors are effective in chronic myelogenous leukemia stem cells appeared after acquisition of imatinib mesylate resistance [37] .
In conclusion, the expression of CD133 or ALDH1 was significantly associated with an unfavorable prognosis. Although a study involving a large number of patients is required before a definite conclusion can be made, our results suggest that the development of a therapeutic strategy that considers the expression of CSC-related markers may be a key to further improvements in the prognosis of patients undergoing trimodality therapy. of the same slide).
